As the mTOR pathway modulates cellular growth via ER signaling and mTOR-pathway activation has been associated with resistance to endocrine therapies before, this observation could provide a rationale to consider the concept of combined mTOR-inhibitor and anti-endocrine therapy as tested in the BOLERO−2 trial also in advanced cervical cancers [17,42]. This evidence concerns the gene MTOR and cervical carcinoma.